Raday Gilead sold $1K of RDHL
Raday Gilead (Chief Operating Officer) sold 14,130,000 shares of RedHill Biopharma Ltd. (RDHL) at $0.00 on 2026-07-10.
How this was made
The 30-second read
Why it matters
Insider selling can affect sentiment, but this specific transaction is very small in dollar terms and does not include new operational or financial guidance.
Market read
Traders may note the insider sale for sentiment monitoring, but the disclosed value is unlikely to drive a fundamental repricing.
What to watch
The filing does not state motives, and the absence of a 10b5-1 plan does not by itself imply negative information without additional context (e.g., repeated sales, option exercises, or material holdings changes).
Background
The article is an SEC Form 4 insider transaction disclosure for RedHill Biopharma Ltd.
Ticker impact
RedHill Biopharma COO Raday Gilead sold 14,130,000 shares in an open-market transaction disclosed on Form 4.
Likely minimal near-term impact; any effect would be sentiment-only and short-lived.
The filing is primary-source, but the transaction value ($1,413) is tiny and there is no 10b5-1 plan disclosed, reducing interpretive weight.
Market effects
No clear sector read-through from a single, low-value insider sale.
None indicated.
None indicated.
Counterpoint
The sale could be administrative liquidity or diversification rather than a bearish view, especially given the extremely low total value.
Key entities
- issuerRedHill Biopharma Ltd.
Subject of the Form 4 insider sale by its COO.
- insiderRaday Gilead
Chief Operating Officer who sold shares via open-market sale.